Finance

Beta
Lists
603087:SHA
Gan & Lee Pharmaceuticals
CN¥54.15
-1.53%
(-0.84) 1D
Jun 3, 3:00:05 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 603087...
Open
CN¥55.00
High
CN¥55.95
Low
CN¥53.85
Mkt. cap
32.85B
Avg. vol.
6.69M
Volume
6.27M
Dividend
1.85%
Quarterly dividend
CN¥0.25
Ex-dividend date
May 29, 2026
P/E ratio
31.28
52-wk high
CN¥82.25
52-wk low
CN¥51.51
EPS
CN¥1.73
No. of employees
5K
Open
CN¥55.00
High
CN¥55.95
Low
CN¥53.85
Mkt. cap
32.85B
Avg. vol.
6.69M
Volume
6.27M
Dividend
1.85%
Quarterly dividend
CN¥0.25
Ex-dividend date
May 29, 2026
P/E ratio
31.28
52-wk high
CN¥82.25
52-wk low
CN¥51.51
EPS
CN¥1.73
No. of employees
5K
News stories
From sources across the web
About Gan & Lee Pharmaceuticals
CEO-
Employees5.31K
FoundedJun 17, 1998
Headquarters-
SectorBiotechnology
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.08B
980.24M
1.01B
878.11M
Cost of goods sold
261.95M
234.89M
259.72M
223.40M
Cost of revenue
261.95M
234.89M
259.72M
223.40M
Research and development expenses
134.08M
143.34M
239.11M
128.04M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
394.33M
384.60M
444.21M
327.25M
Operating expense
537.65M
527.76M
709.00M
462.53M
Total operating expenses
799.60M
762.65M
968.72M
685.94M
Operating income
282.33M
217.59M
36.39M
192.17M
Other non operating income
-60.94M
56.64M
-70.56M
-1.12M
EBT including unusual items
330.63M
234.69M
304.10M
212.64M
EBT excluding unusual items
249.14M
290.23M
257.75M
205.87M
Income tax expense
38.87M
20.03M
-21.15M
20.18M
Effective tax rate
11.76%
8.53%
-6.95%
9.49%
Other operating expenses
9.24M
-209.47K
25.46M
7.75M
Net income
291.76M
214.66M
325.24M
192.49M
Net profit margin
26.97%
21.90%
32.36%
21.92%
Earnings per share
-
-
-
-
Interest and investment income
27.76M
16.11M
303.56M
14.82M
Interest expense
-122.52K
-
-231.14K
-
Net interest expenses
27.64M
16.11M
303.33M
14.82M
Depreciation and amortization charges
-
-
-
-
EBITDA
352.14M
280.34M
110.65M
266.44M
Gain or loss from assets sale
-
-
-3.71M
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more